The bull market for Hong Kong stocks has begun; how to identify the certainty of value growth?

At present, the technical bull market in the Hong Kong stock market is becoming the focus of attention for global investors.

Gelonghui FinanceMar 4 08:44

The Hong Kong stock market for Medical stocks is surging! In February, the strongest has risen over 220%, what happened?

Recently, the General Office of the State Council forwarded the "2025 Action Plan for Stabilizing Foreign Investment" from the Ministry of Commerce and the National Development and Reform Commission, promoting the orderly opening of the Biomedical sector.

Futu NewsFeb 27 14:58

Hong Kong stocks movement | HUA MEDICINE-B (02552) rose nearly 30% in the afternoon. The company has built its own sales team to advance the commercialization process of Huadongning.

HUA MEDICINE-B (02552) rose nearly 30% in the afternoon, as of the time of writing, it rose by 24.12%, trading at 2.11 Hong Kong dollars, with a transaction volume of 20.8871 million Hong Kong dollars.

Zhitong FinanceFeb 19 13:55

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 8 09:59

HUA MEDICINE-B (02552): HUA MEDICINE Shanghai formally delivered a termination notice to Bayer according to the agreement.

HUA MEDICINE-B (02552) announced that on December 31, 2024, HUA MEDICINE in Shanghai will, according to the agreement, supply to Ba...

Zhitong FinanceDec 31, 2024 18:08

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 17:16